Cellectis S.A. (NASDAQ:CLLS) Short Interest Up 41.7% in December

Cellectis S.A. (NASDAQ:CLLS) was the recipient of a significant increase in short interest during the month of December. As of December 31st, there was short interest totaling 400,576 shares, an increase of 41.7% from the December 15th total of 282,762 shares. Based on an average daily volume of 111,087 shares, the short-interest ratio is currently 3.6 days. Currently, 0.7% of the shares of the company are short sold. Currently, 0.7% of the shares of the company are short sold. Based on an average daily volume of 111,087 shares, the short-interest ratio is currently 3.6 days.

Analyst Upgrades and Downgrades

Several analysts recently commented on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Cellectis in a report on Wednesday, October 8th. Wall Street Zen upgraded shares of Cellectis to a “hold” rating in a research report on Saturday, September 20th. Wells Fargo & Company restated a “positive” rating and set a $4.00 price objective on shares of Cellectis in a report on Monday, October 20th. Clear Str raised Cellectis to a “strong-buy” rating in a research report on Tuesday, December 23rd. Finally, Barclays lifted their price target on Cellectis from $4.00 to $8.00 and gave the stock an “overweight” rating in a report on Friday, October 17th. One research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $6.00.

Cellectis Trading Down 0.5%

Shares of NASDAQ:CLLS opened at $4.07 on Friday. Cellectis has a 12-month low of $1.10 and a 12-month high of $5.48. The company’s 50 day moving average price is $4.54 and its two-hundred day moving average price is $3.47. The company has a debt-to-equity ratio of 0.63, a quick ratio of 1.49 and a current ratio of 1.49.

Cellectis (NASDAQ:CLLS) last issued its quarterly earnings results on Friday, November 7th. The biotechnology company reported $0.01 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.10) by $0.11. The business had revenue of $37.16 million during the quarter, compared to analysts’ expectations of $8.22 million. Cellectis had a negative return on equity of 51.22% and a negative net margin of 58.06%. As a group, sell-side analysts predict that Cellectis will post -0.46 earnings per share for the current year.

Institutional Trading of Cellectis

Large investors have recently modified their holdings of the stock. Millennium Management LLC increased its position in shares of Cellectis by 61.9% in the third quarter. Millennium Management LLC now owns 57,740 shares of the biotechnology company’s stock worth $165,000 after purchasing an additional 22,080 shares during the period. Delaney Dennis R acquired a new stake in Cellectis during the third quarter worth about $68,000. B Group Inc. grew its stake in Cellectis by 0.8% during the third quarter. B Group Inc. now owns 3,281,501 shares of the biotechnology company’s stock worth $9,352,000 after buying an additional 25,000 shares in the last quarter. Virtu Financial LLC bought a new position in Cellectis in the 3rd quarter valued at about $72,000. Finally, Acadian Asset Management LLC raised its position in shares of Cellectis by 132.9% in the 1st quarter. Acadian Asset Management LLC now owns 46,377 shares of the biotechnology company’s stock valued at $55,000 after buying an additional 26,461 shares in the last quarter. 63.90% of the stock is owned by institutional investors and hedge funds.

Cellectis Company Profile

Cellectis is a clinical‐stage biopharmaceutical company specializing in the development of gene‐edited cell therapies for oncology. Founded in 1999 and headquartered in Paris, France, the company also maintains operations in New York City and Raleigh, North Carolina. Cellectis applies its proprietary TALEN genome editing platform to engineer allogeneic chimeric antigen receptor T‐cell (CAR‐T) candidates designed to target blood cancers and solid tumors.

The company’s core business activities encompass the discovery, development and manufacturing of off‐the‐shelf immunotherapies.